|
|
||||||||
,1



* INRA, UMR1080 Dairy Production, F-35590 Saint Gilles, France
Agrocampus Ouest, UMR1080 Dairy Production, F-35000 Rennes, France
Organic Dairy Research Centre, Guelph University, Alfred campus, 31 rue St-Paul, PO Box 580, Alfred, Ontario K0B 1A0, Canada
Rowett Institute of Nutrition and Health, University of Aberdeen, Aberdeen AB21 9SB, United Kingdom
# Dairy and Swine Research and Development Centre, Agriculture and Agri-Food Canada, STN Lennoxville, Sherbrooke, Québec J1M 1Z3, Canada
1 Corresponding author: Sophie.Lemosquet{at}rennes.inra.fr
| ABSTRACT |
|---|
|
|
|---|
Key Words: dairy cow glucose metabolism propionic acid casein
| INTRODUCTION |
|---|
|
|
|---|
In the lactating dairy cow, whole-body glucose needs are met primarily from hepatic gluconeogenesis (Danfaer, 1994), although direct intestinal glucose absorption may also contribute for cows fed maize diets (Reynolds, 2006). The major glucose precursor is propionate, produced from rumen fermentation of carbohydrates. Nonetheless, hepatic uptake of propionate does not correlate well with liver glucose release and, indeed, increased propionate supply, via food or ruminal infusions, does not always elicit predicted increments in glucose production (see Kristensen, 2005).
Lactate and AA are also important gluconeogenic precursors (Danfaer, 1994) and the latter may contribute up to 15% to hepatic glucose synthesis. In addition, AA contribute to kidney gluconeogenesis (Heitmann and Bergman, 1980). Indeed, a recent meta-analysis (Lemosquet et al., 2007) showed that glucose Ra increased linearly with intestinal CN infusions. Therefore, observed responses in milk output to CN infusions (Hanigan et al., 1998a) may involve part of the additional AA supply being used to synthesize glucose and thus aid the concomitant secretion of additional milk lactose and protein.
Although CN infusions increase milk yield (Chamberlain and Yeo, 2003), the milk response to propionate (C3) is not always consistent. For example, iso-energetic substitution with C3 increased milk yield in proportion to the amount of glucogenic precursors (C3 plus glucose) absorbed (Rigout et al., 2003), but a positive effect has not always been observed (Hurtaud et al., 1993; Vanhatalo et al., 2003a; Lemosquet et al., 2009). These experiments raised the question of the relationship between lactose synthesis and whole-body glucose availability.
Two studies (Clark et al., 1977; Ranawana and Kellaway, 1977) have examined the effect of postruminal supply of both glucose and CN on the Ra of glucose and milk yield. There was a trend indicating that treatments enhanced glucose Ra whereas only CN increased or tended to increase milk yield; therefore, the authors suggested that this response was not through increased glucose availability. The dose of glucose infused was, however, relatively low compared with that reported by Rigout et al. (2002b), where both glucose Ra and milk yield increased. One critical point is that lactose synthesis depends not only on whole-body glucose availability but also glucose uptake and utilization within the mammary gland. For example, both decreases and increases in the ratio of lactose output to glucose uptake have been observed with duodenal glucose infusions (Vanhatalo et al., 2003a, b). This leads to the additional question of whether glucose uptake per se is a critical determinant of lactose production or if one of the many nutrients that are used by the mammary gland through complex but interactive pathways can substitute to achieve an appropriate balance of milk constituent output.
In summary, the literature on infusions of additional glucogenic precursors (Clark et al., 1977; Lemosquet et al., 2009) did not show a strong positive relationship between increased Ra and increased lactose yield. This raises the key question of how additional energy (C3) and protein (casein) regulate milk volume yield and milk constituent output. Is this accomplished through a common mechanism, perhaps via increased whole-body glucose availability? How much of their independent actions overlap, and is there any interaction when supplied together? These questions formed part of the design of the current experiment that compared how C3 and CN supplies, either separately or in combination, modify both whole-body and mammary glucose metabolism and their effect on utilization of other energy-yielding nutrients in relation to milk yield response. Whole-body protein kinetics and mammary AA metabolism from this study have been reported previously (Raggio et al., 2006a, b).
| MATERIALS AND METHODS |
|---|
|
|
|---|
The infusion of CN or C3 was tested, separately or in combination, according to a 2 x 2 factorial arrangement: duodenal infusion of calcium caseinate (CN; 743 ± 7 g/d, estimated to provide 687 g/d of protein truly digested in the small intestine and 7.9 MJ/d of NEL; Guinard et al., 1994), or ruminal infusion of C3 (1,042 ± 8 g/d, estimated to provide 15.6 MJ/d of NEL; INRA, 1989), or infusion with both CN and C3. Therefore, the 4 treatments were: 1) control, 2) CN, 3) C3, and 4) a combination of both CN and C3 (CN+C3). Each treatment period lasted 14 d.
Diets and preparation of the infusions are detailed in Raggio et al. (2006b). The same basal diet (Raggio et al., 2006b), balanced to provide limited intestinal glucose (Rigout et al., 2003), was fed for the duration of the study. The basal diet was estimated to supply 1,593 g/d of protein truly digested in the small intestine and 124 MJ/d of NEL (INRA, 1989), or 1,624 g/d of metabolizable protein and 119 MJ/d of NEL (NRC, 2001). The concentrate was supplied every 3 h in equal portions from automatic feeders, starting at 0715 h. Grass silage was fed 3 times/d: 25% at 0715 h, 25% at 1315 h, and 50% between 1715 h and 1915 h. To help maintain a steady metabolic state, the silage was fed 5 times/d during the days involving kinetic measurements: 12.5% at 0715, 1015, 1315, and 1615 h, respectively, and 50% at 1915 h. Throughout the entire study, access to the diet was limited to 1 h after each concentrate distribution.
Cows were housed in individual tie stalls and were milked twice daily (0630 h and 1830 h). During the second week of each treatment period, the half udders of each cow were milked separately. The mean values of milk samples taken from the right udder at every milking during the second week were used for calculations.
Sampling and Laboratory Analyses
Milk samples from the right udder were taken at every milking during the second week and were assayed for fat and true protein composition by infrared analysis (MilkoScan, Foss Electric, Hillerød, Denmark). On the morning of d 13, 100 mL of milk from the right udder was stored for chemical analyses. Lactose was analyzed according to Hurtaud et al. (1993) and metabolites in milk were analyzed according to Rigout et al. (2002a), whereas milk fatty acid (FA) composition were determined as described by Couvreur et al. (2006). Ruminal fluid was collected at 0900, 1200, and 1500 h on d 12. The pH was measured immediately and the remainder of the sample was then filtered through 6 layers of muslin and stored at – 20°C before analysis for ammonia and VFA as described by Rigout et al. (2003).
On d 11 of each experimental period, samples were taken from the carotid artery and the mammary vein simultaneously every 2 h between the morning and evening milking (6 samples/vessel in total) to determine blood gases and the plasma concentrations of glucose, acetate, BHBA, lactate, triglycerides, NEFA, and urea. Blood was collected in 2-mL syringes for blood gases (heparin, S-Monovette, Sarstedt, Nümbrecht, Germany) and in 7.5-mL syringes for other parameters (heparin, S-Monovette, Sarstedt). Blood gases were immediately determined using a blood-gas and mineral analyzer (ABL 625, Radiometer, Copenhagen, Denmark). Blood was centrifuged at 2,000 x g for 10 min at 4°C. Plasma was deproteinized with 2 volumes of 0.6 M perchloric acid and filtered for analysis of acetate and lactate. Plasma and deproteinized plasma were stored at –20°C before analysis. Plasma samples for BHBA, NEFA, triglycerides, and deproteinized plasma for acetate and lactate were pooled for each vessel within each cow period just before analyses on a multiparameter analyzer (KONE Instruments Corporation, Espoo, Finland). Enzymatic kits were used for glucose (hexokinase; GLUC HK 07 3672, Roche Diagnostics, Meylan, France), L-lactate (lactate oxidase and peroxidase; Lactate-PAP 61192, Bio-Mérieux S.A., Marcy-lEtoile, France), NEFA (acetyl-CoA synthase, acyl-CoA oxidase and peroxidase; NEFA C Wako kit, Oxoid S.A., Dardilly, France), and urea (urease and glutamate dehydrogenase; Urée UV Cinétique, KONE Diagnostics, Evry, France). Triglycerides were analyzed using a kit (GPO PAP, Biotrol, Biomerieux, Lyon, France) that included lipase, glycerol kinase, glycerol-3-phosphate oxidase, and peroxidase. This analysis corresponds to the sum of free glycerol and triacylglycerol. Acetate was analyzed using the acetyl-CoA synthase and malate dehydrogenase (Sigma, Saint-Quentin Fallavier, France). The analysis of BHBA was performed with BHBA dehydrogenase (Sigma).
The effect of treatments on glucose Ra was measured on d 13 between 1200 h and 1630 h. Solutions of [6,6-2H2]glucose (99 mol% excess; Cambridge Isotope Laboratories, Andover, MA; 60.0 ± 0.5 mg/mL) were sterilized by passage through a 0.22-µm sterile disk filter (Millipore, Saint-Quentin en Yvelines, France). A priming dose (13.2 ± 0.1 mmol of [6,6-2H2]glucose) was injected through one jugular vein catheter and the solution was then continuously infused at 24.9 ± 0.21 mmol/h for 240 min with a syringe pump (Harvard Apparatus, Les Ulis, France). Arterial blood glucose concentrations were monitored by glucometer (LifeScan One Touch, Johnson & Johnson Company, Milpitas, CA) every 10 min (from –20–240 min) to ensure steady-state conditions (within ±5%). Arterial blood for natural abundance measurement was taken into heparinized syringes (S-Monovette, 7.5 mL, Sarstedt) 180 and 60 min before the priming dose and further samples were taken at 105, 150, 195, and 240 min of infusion. Blood was centrifuged at 2,500 x g for 10 min at 4°C and the plasma stored at –20°C. Plasma glucose isotopic enrichments (IE) were measured by selected ion-monitoring electron-impact gas chromatography–mass spectrometry (5917A, Hewlett-Packard, Palo Alto, CA) using 50 µL of plasma. Glucose was converted in trimethylsilyl-O-methyloxime with methoxyamine hydroxychloride (MOX reagent, Pierce Chemical, Rockford, IL) and N,O-bis (trimethylsilyl) trifluroacetamide with 1% trimethylchlorosilane (BSTFA+1% TMCS; Pierce Chemical). Ion mass-to-charge ratios (m/z) were monitored at 319 and 321. The glucose IE (as mole percent excess; MPE) was calculated relative to natural abundance. A reference plasma at 3.31 ± 0.13 MPE was introduced into each batch of analysis. The intra- and interassay coefficients of variation were 5.0 and 5.2%, respectively.
To determine insulin, glucagon, and IGF-1 levels, 5 arterial blood samples were taken at 0900, 1100, 1300, 1430, and 1600 h on d 13 of each period using syringes containing K2-EDTA (1.2–2 mg/mL; S-Monovette, Sarstedt; 7.5 mL for insulin and IGF-I determination and 2.5 mL for glucagon determination). Aprotinin (260 µL; 2,600 KIU; Antagosan, Hoechst Marion Roussel GmbH, Marbourg, Germany), a protease inhibitor, was added to the syringes used to collect blood for glucagon determination. Blood samples were kept on ice and centrifuged at 2,500 x g for 10 min at 4°C. The 3 hormones were analyzed by radioimmunoassay. Insulin and IGF-1 were analyzed as described by Rigout et al. (2002b) and Guinard-Flament et al. (2007), respectively. Glucagon was analyzed using a radioimmunoassay kit (Cliniscience, Linco Research, St. Charles, MI) that involved an antibody specific to pancreatic glucagon and with cross-reactivity to oxyntomodulin, the primary gut glucagon, of <0.1%. The intraassay coefficient of variation of control plasma was 3.2% for insulin, 6.5% for glucagon (all samples were analyzed in a single assay), 3.9% for IGF-1, and the interassay for IGF-1 was 1.8%.
Calculations
Mammary Net Uptake of Nutrients.
The Fick principle, using Phe and Tyr, was used throughout to estimate mammary plasma flow because the probe was not functional for 1 cow (Raggio et al., 2006a). Plasma net uptake of nutrients was calculated as
|
|
|
|
O2 and CO2 Concentrations.
The radiometer ABL 625 analyzer measured pH, partial pressures of O2 and CO2, hemoglobin, and percentage saturation and gave derived values for blood O2 and CO2 concentrations (Siggaard-Andersen et al., 1988) based on maximal saturation of hemoglobin of 1.39 mL of O2/g with a volume of 22.4 L/mol. The hematocrit derived by ABL 625 calculations, and based on human values, was corrected by –2 points to match the values measured directly by centrifugation in cows and sheep (our unpublished data).
Mammary Gland Extraction Rate and Mammary Clearance of Nutrients.
The proportion of mammary arterial flow utilized by the mammary gland on a net basis, mammary gland extraction rate (ER), was calculated using the following equation:
|
|
To obtain information on the capacity of mammary net transport system, the mammary clearance rate (Km) of nutrients was calculated using the model of Hanigan et al. (1998b):
|
|
Whole-Body Glucose Ra.
During the [6,6-2H2]glucose infusion, plasma glucose concentrations were maintained close to steady state (CV = 2.81% ± 1.11%), as were enrichments (CV = 3.48% ± 1.22%). The steady state model was then used to calculate whole body glucose Ra:Ra = F x (IEinf/IEp – 1), where F is the [6,6-2H2]glucose infusion rate (mmol/h), IEinf is the IE of the infusate (99 MPE), and IEp is the IE of the arterial plasma [6,6-2H2]glucose.
Estimated Mammary Carbon Balances.
The present mammary carbon net balance used similar principles to those adopted by Waghorn and Baldwin (1984) and by Hanigan and Baldwin (1994). Uptakes included glucose, acetate, BHBA, all AA (Raggio et al., 2006a), and glycerol (from triacylglycerol and free glycerol), whereas output involved lactose, glycerol required for milk triglycerides, FA synthesized in the mammary gland, and CO2 production. The present estimated carbon balance excluded exogenous long-chain FA uptake and milk output, as suggested by Waghorn (1982) and Waghorn and Baldwin (1984). In contrast to Waghorn and Baldwin (1984), however, exogenous long-chain FA were not considered to be oxidized because no appreciable catabolism was detected during tracer studies in the mammary gland of fed goats (Annison et al., 1967). Fatty acid yields for carbon balance were calculated using fat yield, based on the hypotheses that 1) all, instead of 98%, of the FA in milk are triglycerides (Palmquist et al., 1969) and 2) each triglyceride (TG) has the following composition:
![]() |
|
|
Statistical Analyses
The original design was a 4 x 4 Latin square design, but 1 of the 4 cows did not recover well after surgery. The experiment was then redesigned as 2 incomplete 4 x 3 Youden squares with 3 periods each for a total of 17 observations [control = 5; C3 = 5; CN = 3 (1 missing value because of a problem with the arterial catheter) or 4; CN + C3 = 4].
Analyses of variance were performed using the MIXED procedure of SAS (SAS Institute, 2004) according to the following statistical model:
![]() |
0.05 and tendency at 0.05 < P
0.10. | RESULTS |
|---|
|
|
|---|
|
|
0.01) during CN treatments and represented 13.2 and 46.4%, respectively, of the additional FA yield. Infusion of C3 did not affect these FA. The yield of C16:0 plus C16:1 was not modified by any treatment. The yield of total C18 decreased (P < 0.001) with C3 and this represented 81.8% of the overall decrease in FA yield. In contrast, total C18 increased (P = 0.02) with CN. The yield of odd-chain FA increased (+17.7%; P < 0.001) with C3 but remained unchanged with CN.
|
|
|
|
Arterial concentration of plasma lactate (Table 6) remained unchanged with C3 and CN treatments but the AV difference, extraction rate, Km, and net uptake all increased (P < 0.01) with C3.
Fat Precursor Metabolism, O2 Consumption, and CO2 Production
Arterial concentrations of acetate, BHBA, NEFA, and triglycerides decreased (P < 0.01) with C3 treatment, as did the AV differences of acetate, BHBA, and triglycerides. In addition, the extraction rates of triglycerides tended (P = 0.07) to decrease with C3 but triglycerides Km did not change. The acetate Km increased (P < 0.01) with C3 treatment. Uptake of BHBA decreased (P < 0.04) and release of NEFA across the mammary gland tended (P = 0.06) to increase with C3, whereas extraction rate tended (P = 0.07) to be more negative and Km (P = 0.03) was more negative in C3 treatments. In contrast, CN treatments did not change arterial plasma concentrations nor AV differences of fat precursors, except for BHBA (Table 6). Arterial concentration of BHBA tended (P = 0.08) to increase during CN treatments and there were CN x C3 interactions for AV difference (P < 0.01) and net uptake (P = 0.06) of BHBA, in that both increased when CN was infused alone but not in the presence of C3. Net uptake of acetate also tended (P = 0.09) to increase with CN treatments.
Arterial concentrations of blood O2 and CO2 were not affected by C3 or CN treatments. However, blood O2 AV differences decreased (P < 0.01) with C3 and increased (P = 0.03) with CN. Blood CO2 AV differences became less negative (P = 0.01) with C3 but more negative (P = 0.02) with CN, although to a lesser extent when CN was infused with C3 (CN x C3 interaction; P = 0.04). Net uptake of blood O2 and net release of blood CO2 did not change with treatments. The changes in AV differences of CO2 and O2 led to a CN x C3 interaction (P = 0.04) for the respiratory quotient that increased when C3 was given alone but decreased when C3 and CN were supplied together.
Milk Metabolites
Milk concentrations (Table 7) of glucose-6-P and glycerol-3-P increased (P < 0.01) during C3 treatments, whereas malate was reduced (P = 0.01). The ratio of 2-oxoglutarate to isocitrate, a reflection of the activity of a major pathway for production of NADPH, was not affected by treatments. Casein treatments tended (P = 0.07) to decrease pyruvate concentrations in milk.
|
| DISCUSSION |
|---|
|
|
|---|
Whole-Body Ra of Glucose Increased with C3 and CN.
Despite the differences in milk output responses, both C3 and CN increased glucose Ra separately. The net increases in glucose carbon averaged 0.31 of the carbon infused for both C3 and CN alone. In earlier studies (Lemosquet et al., 2004, 2009; see Kristensen, 2005 for a review), based on ruminal C3 supplementation, the conversions of propionate to glucose were only 30 to 40% of that expected theoretically. In the present experiment, the whole-body CO2 entry rate was increased when C3 was supplemented (Raggio et al., 2006b). This suggests increased nutrient oxidation, either of C3 directly as observed in steers (Veenhuizen et al., 1988), or of other metabolites whose gluconeogenic role may be replaced by C3. In either case, the apparent efficiency of conversion of C3 to glucose would be less than theoretical.
If all of the AA infused as CN were used in gluconeogenesis (Van Milgen, 2002), the increment of Ra would maximally represent 0.48 of the carbon infused as CN. In CN treatment, the apparent conversion efficiency of the infused CN carbon to glucose carbon (based on the increment in glucose Ra) was only 0.31, but when allowance was made for the CN required to support the extra milk protein output then the ratio increased to 0.40. Close matches between observed and theoretical values have been reported previously (Clark et al., 1977; König et al., 1984; see Lemosquet et al., 2007 for meta-analysis).
Besides the additional gluconeogenic precursors provided by the CN infusions, other mechanisms may also operate to affect Ra. For example, CN alone increased glucagon concentration. Glucagon may act to limit the action of insulin on inhibition of hepatic gluconeogenesis. In addition, glucagon stimulates glycogenolysis, another source of plasma glucose. Glucagon also increases the rate of protein breakdown and the uptake of AA by the liver, providing further gluconeogenic precursors (Danfaer, 1994). Unfortunately, the current data do not allow these various mechanisms to be separated. Furthermore, the changes in glucose Ra need to be interpreted carefully because these involve a composite of gluconeogenesis, glycogenolysis, and glucose absorption, although the latter is probably minor in the present experiment. Increases of plasma glucagon and glycogen turnover were observed in muscle and the hearts and livers of rats fed CN (Gannon and Nuttal, 1988, 1995). Indeed, changes in Ra need not necessarily represent altered net supply of glucose because increased glycogen turnover, through concurrent elevation of glycogenolysis and glycogen synthesis, would increase glucose Ra but not provide additional glucose for lactose synthesis. When C3 was infused with CN, the increase in plasma glucagon was suppressed (interaction at P = 0.04) and this may limit the involvement of some of the mechanisms described above in either altered glucose supply or Ra when additional protein and energy are supplied together.
No Direct Link Between Increased Ra of Glucose and Lactose Yield.
In the present experiment, the Ra of glucose was increased by either the C3 or CN infusions and yet only the latter increased milk yield and lactose output. Therefore, glucose availability, as assessed by glucose Ra, does not seem to be the driving mechanism (or "push") to increase lactose synthesis. Similarly, increments in glucose Ra in response to other gluconeogenic sources, such as NEAA (1,440 g/d) and C3, or directly to glucose infusions also failed to elicit an increased milk yield (Lemosquet et al., 2009).
Lactose Synthesis Not Linked to Mammary Glucose Uptake
In the present experiment, mammary glucose uptake was not increased with either C3 or CN treatments, but the latter resulted in greater lactose yield whereas the former did not. The C3 treatment led to increased (+28.3%) mammary plasma flow and decreased (–14.8%) glucose AV difference, such that net glucose uptake was not altered significantly. Such opposing changes in mammary plasma flow and AV difference have been reported previously in response to increases in either glucose supply (Rigout et al., 2002b; Vanhatalo et al., 2003b) or feed intake (Guinard-Flament et al., 2007). Increased feed intake (particularly energy supply) is accompanied by elevated cardiac output and heart rate (Guinard-Flament et al., 2007) and this leads to increased portal blood flow (Wieghart et al., 1986). Therefore, because total energy intake was increased by the current treatment (basal diet plus C3 infusions), this may lead to greater systemic blood flows, including at the mammary gland. The fact that mammary uptake did not increase whereas mammary arterial plasma supply increased (decreased extraction rate) suggests that glucose uptake is regulated, in part, by factors within the mammary gland (Madsen et al., 1999).
With CN treatments, the unchanged glucose uptake was a consequence of decreased (–19%) mammary plasma flow and increased (+19%) glucose AV, with both parameters altering in the opposite direction to the findings with C3. This finding was somewhat surprising because previous studies in this laboratory had not shown any decrease in mammary plasma flow, measured either with an ultrasonic flow probe (Guinard et al., 1994) or by the Fick principle (Raggio et al., 2004), in response to increased protein supply. Furthermore, no relationship was found between protein intake and mammary plasma flow based on a meta-analysis of the available literature (Lemosquet et al., 2007). In the current study, plasma flow was estimated by the Fick method using Phe and Tyr as AA markers as in Raggio et al. (2004), but almost identical estimates were obtained when comparisons were based on Met (Raggio et al., 2006a), as has been observed in other studies (Rulquin et al., 2007). While a systematic underestimate of blood flow may occur through mammary gland uptake of peptides, such concerns usually exist only with low protein supply (Bequette et al., 1999). Indeed, any such error in the current study is probably relatively small based on the observations that mammary N balance was not different from zero in either the control or CN treatments (Raggio et al., 2006a); this is supported by corresponding agreements for the carbon balance reported here (see below). Furthermore, the mammary gland does exhibit considerable flexibility in response to AA supply. For example, when His supply to support mammary metabolism was increased from deficient to adequate, this increase was accompanied by reduced blood flow and altered transport kinetics for His (Bequette et al., 2000). Indeed, increased arterial concentrations for many of the essential AA, including His, resulted from the CN supplementation (Raggio et al., 2006b) and this improved availability may have led to the decreased plasma flow observed in the current study.
Regulation Through Intramammary Metabolism
In line with the lack of change in net glucose uptake in response to C3 and CN treatments, there were no differences observed in glucose Km. This suggests that the capacity of the glucose transport systems was not affected, in agreement with Xiao and Cant (2005) who proposed that intramammary events, such as phosphorylation of the glucose, were important control steps. The trend of a decreased ratio of lactose yield relative to glucose uptake with C3 treatments suggests that mammary glucose was used for metabolic purposes other than lactose synthesis with C3. With CN treatments, despite no change in net glucose uptake, there was increased lactose production so that the utilization of intramammary glucose differed from C3. This also meant that, for CN, some of the outcomes of mammary glucose metabolism during the control and C3 treatments will need to be substituted by other substrates and this can be explored through consideration of the various metabolites that contribute to the carbon balance monitored in the present experiment.
Within the mammary gland, glucose is necessary to support activities related to the extra milk synthesis, including lactose and glycerol synthesis, carbon for NEAA synthesis, and NADPH and ATP requirements for triglyceride and protein synthesis (Smith et al., 1983). If more (or less with C3) glucose is diverted to lactose synthesis, the metabolism of other metabolites must increase (or decrease) in compensation. This forms the basis of the partial carbon balance (mmol/h; Table 8) performed. Based on the hypotheses and assumptions detailed in the Materials and Methods section, mammary net carbon balances were not significantly different from zero (range = –119 to +112 mmol of C/h) and, indeed, output accounted for 98.6 to 107.0% of uptake. While such accounting suggests that the major contributors to carbon exchanges across the mammary gland have been included, no allowance was included for any variation in the contribution of exogenous FA to the proportion of milk C16 FA. In addition, these FA were not considered to be oxidized within the mammary gland.
|
Ruminal C3 treatment decreased long-chain FA concentration in milk and, consequently, milk fat yield, as already observed (Hurtaud et al., 1998), but this was more pronounced than if C3 was provided as an energy substitute (Rigout et al., 2003). This is probably related to altered supply of long-chain FA because these are not synthesized within the mammary gland but instead are derived from plasma triglycerides. Arterial concentrations of triglycerides, NEFA, BHBA, and acetate decreased with C3 treatment, which suggests lowered whole-body availability of fat precursors. Indeed, across the mammary gland, uptake of BHBA was reduced whereas net release of NEFA increased. Similar arterial and mammary responses, leading to lowered long-chain FA yield in milk, have been observed during duodenal glucose infusions (Rigout et al., 2002a).
Intramammary Regulation of Lactose Synthesis with CN.
Simple consideration of the carbon balance on the CN treatment clearly shows a degree of metabolic switching, and to a greater degree than observed for C3. In addition to the increased ratio of lactose output to glucose uptake (Table 5), there was a tendency for reduced net balance (Table 8) between glucose uptake and the combined outputs of lactose and glycerol (in triglycerides). This reflects that more glucose was diverted to anabolic products (notably lactose) with less to support other processes, such as energy supply. These latter roles are then substituted, in part, by extra BHBA uptake, observed for CN alone; however, it cannot be resolved whether the diversion of more glucose to lactose stimulates greater BHBA removal or whether uptake of the latter spares glucose oxidation and releases more carbon for anabolic fates. The only direct measure of altered oxidation in the current study involved Leu, which increased 2-fold in CN treatments (Raggio et al., 2006a). This would provide acetyl-CoA for energetic purposes and to support milk fat synthesis. There were also positive net carbon balances for the other branched-chain AA (Raggio et al., 2006a) and if these, and other AA, had also increased oxidation then this would provide 3-carbon intermediates that could substitute for glucose in a variety of metabolic pathways (Bequette et al., 2006). Indeed, tracer studies in vitro with mammary gland explants from goats (Roets et al., 1983; Bequette et al., 2006) have shown incorporation of AA-carbon into lactose (most essential AA) and milk fat (Leu). Care is needed, however, in the interpretation of kinetic fluxes between nutrients with isotope studies sharing common pathways because part of the transfer of an isotope may just be the result of a reciprocal exchange between 2 metabolites rather than a net gain in one direction.
Interactions Between CN and C3 Could Be Linked to Oxidative Process
The C3 and CN treatments separately demonstrated the different influences on milk production and the metabolic adaptability of the mammary gland to respond to varied nutrient supplies. The important question is, "Do these energy and protein supplies act in a competitive or additive manner when given in combination?" In the present experiment only a few interactions were statistically significant: rumen NH3 concentrations, whole-body Leu oxidation (Raggio et al., 2006b), Ala and BHBA uptake, and respiratory quotient across the mammary gland. Several of these interactions are probably linked to altered nutrient oxidation. For example, the addition of C3 to CN greatly reduced the extra BHBA extracted by the mammary gland compared with CN alone. Thus, the need to use the ketone body, either to provide energy or as a precursor for lipid synthesis, is reduced markedly when another available energy source is provided. Another example is the observed reduction in whole-body Leu oxidation (Raggio et al., 2006b) when protein and energy supply were both increased, with more of the exogenous AA supplied converted into milk protein and less oxidized to provide ATP. The additional response to CN+C3 also means that maximal output of the gland was not achieved with either CN or C3 alone, so neither provided a complete substitute for the other. This improvement may be linked to the reduction in plasma glucagon when C3 was added to the CN supply because this hormone stimulates hepatic oxidative metabolism (Veenhuizen et al., 1988). Again, it is unclear whether the glucagon response reduces nutrient catabolism, thus leaving more for anabolic use by the mammary gland, or whether the hormone responds to the lowered surplus after the various removals by the mammary gland.
| CONCLUSIONS |
|---|
|
|
|---|
| ACKNOWLEDGMENTS |
|---|
|
|
|---|
Received for publication January 6, 2009. Accepted for publication August 9, 2009.
| REFERENCES |
|---|
|
|
|---|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |